CD19 and systemic lupus erythematosus: used anti-CD19 CAR-T cells to complete the continuous and effective consumption of B cells in SLE mouse models, and the duration was higher than that of antibodies, and improved the disease of SLE, delayed its occurrence, which played a good preventive role, and showed the potential clinical efficacy of CAR-T therapy on SLE (300).